Emerging Hypervirulent Marek’s Disease Virus Variants Significantly Overcome Protection Conferred by Commercial Vaccines

Jinling Liu, Man Teng, Luping Zheng, Feng-Xia Zhu, Shu-Xue Ma, Linyan Li, Zhi‐Hui Zhang, Shujun Chai, Yongxiu Yao, Jun LuoViruses 2023 · DOI

TL;DR

This study investigates the alarming rise of hypervirulent Marek's Disease Virus (MDV) strains in China, which are increasingly causing outbreaks in vaccinated chicken flocks. The research demonstrates that these emerging strains significantly evade protection from currently used commercial vaccines, highlighting an urgent need for new vaccine development to combat this threat to the poultry industry.

What Problem Does This Paper Address?

Marek's disease (MD) is a major concern in the global poultry industry, causing significant economic losses due to its immunosuppressive and neoplastic effects on chickens. While commercial vaccines have been instrumental in controlling MD for decades, recent years have seen a concerning increase in MD outbreaks in vaccinated flocks. This suggests that the virus is evolving, potentially becoming more virulent and overcoming vaccine-induced immunity. The exact nature of these emerging strains and their impact on vaccine efficacy remained unclear, prompting this research to analyze newly isolated MDV strains and evaluate the effectiveness of current vaccines against them.

Methods

The researchers employed a multi-pronged approach:

  • Pathogenicity and Oncogenicity Analysis: Seven newly isolated MDV strains from tumor-bearing chickens in China were used to infect SPF (specific pathogen-free) chickens. The birds were monitored for clinical signs, mortality, and tumor development over 73 days. Immune organ weights (thymus, bursa, spleen) were also assessed to evaluate immunosuppression.
  • Vaccine Efficacy Evaluation: A separate experiment involved vaccinating SPF chickens with four commercially available MD vaccines (CVI988, HVT, CVI988+HVT, and 814). These vaccinated birds, along with unvaccinated controls, were then challenged with one of the highly virulent MDV strains (SDCW01). The study monitored mortality, tumor incidence, and calculated Protection Indices (PIs) to quantify vaccine effectiveness.
  • Statistical Analysis: Standard statistical methods, including ANOVA, Z-tests, and Log-rank tests, were used to compare groups and determine the significance of observed differences in morbidity, mortality, tumor incidence, and survival rates.

Datasets

Not discussed in the paper. The study utilized newly isolated MDV strains and commercially available vaccines.

Key Insights and Ideas

  • Emergence of Hypervirulent Strains: The study confirms the prevalence of hypervirulent MDV (HV-MDV) variants in China, with four out of seven newly isolated strains exhibiting significantly high pathogenicity and oncogenicity.
  • Vaccine Evasion is Real: The most striking finding is that these emerging HV-MDV strains can significantly break through the immune protection offered by widely used commercial MD vaccines. This is evidenced by the low Protection Indices (PIs) observed.
  • Monovalent Vaccines Show Limited Efficacy: Even monovalent vaccines (CVI988 or HVT) failed to provide complete protection, with vaccinated birds still developing tumors.
  • Co-epidemics of MDV Strains: The data suggests the co-circulation of MDV strains with varying virulence levels in Chinese chicken flocks, indicating a complex evolutionary landscape.
  • Implications for Poultry Health: The findings underscore a critical challenge for the poultry industry, as current vaccination strategies may no longer be sufficient to prevent devastating MD outbreaks.

Key Results

  • High Pathogenicity of New Strains: Four newly isolated MDV strains (SDCW01, HNXZ05, HNSQ05, and HNSQ01) demonstrated high pathogenicity, leading to 100%, 93.3%, 90%, and 100% MD incidence, respectively, with mortalities ranging from 60% to 86.7% within 73 days. Tumor occurrences were also substantial, reaching up to 63.3%.
  • Significant Immune Organ Atrophy: Infected birds showed significant atrophy of immune organs (thymus and bursa), indicating severe immunosuppression.
  • Low Vaccine Protection Indices (PIs): When challenged with the SDCW01 strain, the four commercial MD vaccines showed unexpectedly low PIs: CVI988 (46.2%), HVT (38.5%), CVI988+HVT (50%), and 814 (28%).
  • Tumor Development in Vaccinated Birds: Even vaccinated birds developed tumors, with cumulative incidences of 7.7% for CVI988 and 11.5% for HVT. The bivalent CVI988+HVT and the 814 vaccine showed better results, with 0% tumor incidence in surviving birds.

Limitations and Future Work

  • Experimental Timeframe: The study's virus-challenge experiments had to be terminated early due to COVID-19 restrictions, which might have influenced the final tumor incidence rates, particularly for the HVT-vaccinated group. The authors speculate that a longer observation period could have revealed even lower PIs.
  • Single Strain Challenge: While SDCW01 is a highly virulent strain, the vaccine efficacy was only tested against this single strain. Future work should evaluate vaccine performance against a broader range of emerging HV-MDV strains.
  • Need for Novel Vaccines: The authors strongly advocate for the urgent development of new, more effective MD vaccines. They suggest exploring vaccines based on meq gene-deleted strains or other novel approaches that can provide robust protection against the evolving HV-MDV variants.
  • Further Genetic Analysis: The paper mentions ongoing whole-genome sequencing and phylogenetic analysis of these strains to identify the specific genetic determinants responsible for their increased virulence and vaccine evasion. This research is crucial for understanding the evolutionary mechanisms driving these changes.

Summary updated

Abstract

As one of the most important avian immunosuppressive and neoplastic diseases, Marek's disease (MD), caused by oncogenic Marek's disease virus (MDV), has caused huge economic losses worldwide over the past five decades. In recent years, MD outbreaks have occurred frequently in MD-vaccinated chicken flocks, but the key pathogenic determinants and influencing factors remain unclear. Herein, we analyzed the pathogenicity of seven newly isolated MDV strains from tumor-bearing chickens in China and found that all of them were pathogenic to chicken hosts, among which four MDV isolates, SDCW01, HNXZ05, HNSQ05 and HNSQ01, were considered to be hypervirulent MDV (HV-MDV) strains. At 73 days of the virus infection experiment, the cumulative incidences of MD were 100%, 93.3%, 90% and 100%, with mortalities of 83.3%, 73.3%, 60% and 86.7%, respectively, for the four viruses. The gross occurrences of tumors were 50%, 33.3%, 30% and 63.3%, respectively, accompanied by significant hepatosplenomegaly and serious atrophy of the immune organs. Furthermore, the immune protection effects of four commercial MD vaccines against SDCW01, CVI988, HVT, CVI988+HVT, and 814 were explored. Unexpectedly, during the 67 days of post-virus challenge, the protection indices (PIs) of these four MD vaccines were only 46.2%, 38.5%, 50%, and 28%, respectively, and the birds that received the monovalent CVI988 or HVT still developed tumors with cumulative incidences of 7.7% and 11.5%, respectively. To our knowledge, this is the first demonstration of the simultaneous comparison of the immune protection efficacy of multiple commercial MD vaccines with different vaccine strains. Our study revealed that the HV-MDV variants circulating in China could significantly break through the immune protection of the classical MD vaccines currently widely used. For future work, there is an urgent need to develop novel, more effective MD vaccines for tackling the new challenge of emerging HV-MDV strains or variants for the sustainable control of MD.
BibTeX
@inproceedings{liu2023emerging,
  author = {Jinling Liu and Man Teng and Luping Zheng and Feng-Xia Zhu and Shu-Xue Ma and Linyan Li and Zhi‐Hui Zhang and Shujun Chai and Yongxiu Yao and Jun Luo},
  title = {{Emerging Hypervirulent Marek’s Disease Virus Variants Significantly Overcome Protection Conferred by Commercial Vaccines}},
  booktitle = {Viruses},
  year = {2023},
  doi = {10.3390/v15071434},
}
Figure